Psychedelic Stock Review Initiates Coverage on Ehave Inc.

MIAMI, Sept. 30, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today the Psychedelic Stock Review has initiated coverage.

“Ehave is about to release a number of digital information tools and services made to enhance the effectiveness and practicality of Psychedelic treatments, for both patients and the medical community,” stated Roland Rick Perry, editor of the Biotech and Psychedelic Stock Reviews. Adding, “In 2019 Ehave sold its Clinical Software Platform to Zyus Life Sciences a biopharmaceutical company that offers patients cannabinoid and other phyto-therapeutic medical solutions for $3.2 million.”

Ben Kaplan CEO of Ehave stated, “With the successful sale of the cannabis centric platform that contained components specifically designed to be used by medical cannabis patients to efficiently gather and verify patient-reported outcomes and experiences, evaluate treatment progress, enhance patient engagement and improve data modeling we transitioned the Company to providing these same patient reporting and monitoring services to the Psychedelic industry.”

Psychedelic Stock Review Initiates Coverage on Ehave Inc.


What exactly is a favorite?

First what it isn’t. In early August our research team conducted an exhaustive review of all the publicly traded companies, which were primarily or secondarily involved in the nascent business of advancing Psychedelic medical technology.

We’ll soon release a guide called the 2021 Psychedelic Investors Guide which profiles the charts, business intentions and recent news from each of the 44 companies.



Time-stamped @$0.025. Come back a year from now and check the subsequent high.

*Client, see report for disclosure and disclaimer details.